CLEVELAND, April 26, 2017 – OptiKira founders Dr. Feroz Papa (UCSF), Dr. Bradley Backes (UCSF), and Dr. Dustin Maly (University of Washington) have published research showing that direct targeting of IRE1α, using mono-selective KIRA8, reverses autoimmune diabetes in mouse models. Read full Cell Metabolism article here.